138 related articles for article (PubMed ID: 30692483)
1. [A Case of Unresectable Pancreas Cancer with 32 Months Survival after Chemotherapy].
Amagasa H; Fukuda A; Yamada A; Kakuta R; Kajiyama D; Kawaguchi M; Shibuya G; Maeda S; Motoyama K; Ganno H; Imai K; Ami K; Iida S; Andou M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2417-2419. PubMed ID: 30692483
[TBL] [Abstract][Full Text] [Related]
2. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
Nakamoto S; Nishiyama R; Kaneda T; Yokota M; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Yamauchi H; Okuwaki K; Iwai T; Imaizumi H; Suzuki E; Hara A; Ichinoe M; Kida M; Watanabe M
Gan To Kagaku Ryoho; 2017 Feb; 44(2):173-176. PubMed ID: 28223678
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
Kaneko T; Sugimori K; Tozuka Y; Fukushima T; Okada K; Oka H; Okazaki H; Maeda S
Clin J Gastroenterol; 2019 Oct; 12(5):484-489. PubMed ID: 30993653
[TBL] [Abstract][Full Text] [Related]
4. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
[TBL] [Abstract][Full Text] [Related]
5. GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report.
Yoshii H; Izumi H; Abe R; Tajiri T; Mukai M; Nomura E; Makuuchi H
Tokai J Exp Clin Med; 2019 Dec; 44(4):85-89. PubMed ID: 31768996
[TBL] [Abstract][Full Text] [Related]
6. Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Relias V; Maloney A; Smith MH; Saif MW
Cancer Chemother Pharmacol; 2017 Aug; 80(2):371-375. PubMed ID: 28664225
[TBL] [Abstract][Full Text] [Related]
7. Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine.
Boeck S; Haas M; Kruger S; Heinemann V
In Vivo; 2014; 28(6):1189-92. PubMed ID: 25398821
[TBL] [Abstract][Full Text] [Related]
8. [Experience with Gemcitabine plus Nab-Paclitaxel Therapy for Advanced Metastatic Pancreatic Cancer in Our Hospital].
Hagino S; Nakayama A; Sakamoto K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1671-1673. PubMed ID: 28133094
[TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
10. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
Sai S; Toyoda M; Tobimatsu K; Satake H; Yasui H; Kimbara S; Koyama T; Fujishima Y; Imamura Y; Funakoshi Y; Kiyota N; Toyama H; Kodama Y; Minami H
Cancer Chemother Pharmacol; 2021 Jan; 87(1):65-71. PubMed ID: 33098471
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
14. [A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Kuwayama N; Natsume T; Kainuma O; Maruyama T; Tanaka H; Miyazaki A; Sato Y; Note H; Yoshioka T; Matsumoto Y; Suzuki K; Kato M; Oshima S; Ishigaki A; Mizumoto H; Shimizu S
Gan To Kagaku Ryoho; 2019 Apr; 46(4):721-724. PubMed ID: 31164515
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
Cascinu S; Berardi R; Bianco R; Bilancia D; Zaniboni A; Ferrari D; Mosconi S; Spallanzani A; Cavanna L; Leo S; Negri F; Beretta GD; Sobrero A; Banzi M; Morabito A; Bittoni A; Marciano R; Ferrara D; Noventa S; Piccirillo MC; Labianca R; Mosconi C; Casadei Gardini A; Gallo C; Perrone F
Eur J Cancer; 2021 May; 148():422-429. PubMed ID: 33812334
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
Feliu J; Jorge Fernández M; Macarulla T; Massuti B; Albero A; González González JF; Quintero-Aldana G; Delgado-Mingorance JI; Fernández Montes A; García Piernavieja C; Valladares-Ayerbes M; López Muñoz AM; Mondéjar Solís R; Vicente P; Casado Gonzalez E; González Cebrián I; López-Vivanco G
Cancer Chemother Pharmacol; 2021 Apr; 87(4):543-553. PubMed ID: 33452559
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
Yamada S; Fujii T; Yokoyama Y; Kawashima H; Maeda O; Suzuki K; Okada T; Ono E; Yamaguchi J; Takano N; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Kodera Y
Cancer Chemother Pharmacol; 2018 May; 81(5):815-821. PubMed ID: 29502139
[TBL] [Abstract][Full Text] [Related]
18. [Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case].
Kataoka K; Matsubara H; Urano F; Okamura S; Maeda M
Nihon Shokakibyo Gakkai Zasshi; 2016; 113(10):1777-1784. PubMed ID: 27725467
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
20. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]